PMID- 11188771
OWN - NLM
STAT- MEDLINE
DCOM- 20010301
LR  - 20071114
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 6 Suppl 2
DP  - 2000 Oct
TI  - Antibody-mediated remyelination: relevance to multiple sclerosis.
PG  - S1-5; discussion S33
AB  - Intravenous immunoglobulin (IVIG) is widely used for treatment of autoimmune 
      neurological disorders and is currently in clinical trials as a therapy for 
      multiple sclerosis. We have previously demonstrated that certain mouse monoclonal 
      antibodies of the IgM isotype, promote significant remyelination when 
      administered to mice with chronic Theiler's murine encephalomyelitis 
      virus-induced demyelinating disease. These IgM antibodies bind to antigens 
      expressed on oligodendrocytes. We now demonstrate that polyclonal human IgG 
      (IVIG) and polyclonal human IgM also promote remyelination in this system. 
      Although both polyclonal human IgG and IgM promote remyelination, IgM is more 
      potent. Polyclonal human IgM also differs from human IgG in its ability to bind 
      strongly to antigens expressed in the CNS and by oligodendrocytes. We propose 
      that polyclonal IgG and polyclonal IgM may function to promote remyelination by 
      different mechanisms. IVIG may function based on its immunomodulatory activity, 
      while the activity of IgM is critically dependent upon its reactivity with CNS 
      antigens. This possibility has clear relevance to the use of antibodies as a 
      therapy for multiple sclerosis, suggesting that combined treatment with 
      antibodies exerting immunomodulatory activity, in concert with antibodies that 
      function through direct binding to CNS antigens, may synergize to enhance the 
      efficacy of the therapy.
FAU - Bieber, A
AU  - Bieber A
AD  - Department of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, 
      USA.
FAU - Asakura, K
AU  - Asakura K
FAU - Warrington, A
AU  - Warrington A
FAU - Kaveri, S V
AU  - Kaveri SV
FAU - Rodriguez, M
AU  - Rodriguez M
LA  - eng
GR  - NS24180/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Antibodies)
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Antibodies/*therapeutic use
MH  - Autoantibodies/therapeutic use
MH  - Demyelinating Diseases/drug therapy
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunoglobulin G/therapeutic use
MH  - Immunoglobulin M/therapeutic use
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Multiple Sclerosis/*drug therapy
MH  - Myelin Sheath/*drug effects/physiology
RF  - 34
EDAT- 2001/02/24 12:00
MHDA- 2001/03/07 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/03/07 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
PST - ppublish
SO  - Mult Scler. 2000 Oct;6 Suppl 2:S1-5; discussion S33.